Probiotics in Diabesity: A Pilot Study (Diabesity)
|ClinicalTrials.gov Identifier: NCT02469558|
Recruitment Status : Completed
First Posted : June 11, 2015
Last Update Posted : February 6, 2020
Obesity and type 2 diabetes are a pandemic disease leading to a high morbidity and mortality. Probiotic modulation of gut flora is a possible therapeutic mechanism.
The aim of this study is to investigate and compare thoroughly the effect of a multispecies probiotic on glycaemic control, gut microbiota and gut permeability in patients with metabolic syndrome and diabetes.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Obesity||Dietary Supplement: Winclove 851 and 110 Dietary Supplement: Placebo||Not Applicable|
Obesity and diabetes probably represent the most challenging threat to public health in the 21st century. The World Health Organization (WHO) predicts that by 2015 approximately 2.3 billion adults will be overweight (BMI 25-29.9 kg/m²), and more than 700 million will be obese (BMI 30 kg/m² or more). In addition, currently 285 million people worldwide suffer from type 2 diabetes (T2DM), and this number is predicted to increase to 439 million by 2030. T2DM raises the risk for cardiovascular morbidity and mortality, as well as eye problems, nerve damage and kidney diseases. Previous studies demonstrated that the impact of diabetes on everyday life and the likelihood of costly and disabling complications can be reduced by more intensive management of glucose, blood pressure and cholesterol. Weight reduction is the most desired but also most difficult to achieve treatment option in obesity, that is able to prevent secondary complications of obesity and T2DM.
Since weight reduction by diet and increased physical activity alone is difficult to achieve in morbidly obese subjects, other, more aggressive approaches, such as bariatric surgery have been invented.
Recent preclinical and clinical studies have indicated an important influence of the intestinal microbiome (gut metagenome) on obesity and associated metabolic disorders (metabolic syndrome, type 2 diabetes, metabolic liver diseases, cardiovascular diseases). For instance, the cecum microbiota of rodents was found to be significantly different in obese than in lean mice. This finding of altered gut microbiota was then confirmed and extended to humans. Additionally, these investigations in humans demonstrated that as obese people lose weight, the composition of microflora shifted, and more closely resembled that of the lean individuals. This suggests that the microflora might be involved in the pathogenesis of obesity, insulin resistance and T2DM by having an impact on gut permeability and chronic inflammation. Probiotic, prebiotic or synbiotic interventions have been shown to be effective in modulating gut permeability and gut microbiota in animals and thereby modulating chronic inflammation and metabolic disorders in animal models. In humans this has not been shown unequivocally so far.
However, it is yet unknown, who will benefit from which intervention and why individuals respond differently to these interventions.
The aim of this study is to investigate and compare thoroughly the effect of a multispecies probiotic on glycaemic control, gut microbiota and gut permeability in patients with metabolic syndrome and diabetes. The investigators aim to access changes in insulin sensitivity, islet function and the secretion of gut hormones. In addition, the investigators will investigate changes in gut microbiota and gut permeability to understand the underlying mechanism. After investigating the mechanism the overarching aim is to identify biomarkers, which would allow better prediction of treatment success. In future this would allow tailoring obesity and diabetes treatment in order to give every patient the optimal treatment at lowest costs.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Probiotics in Diabesity: A Pilot Study|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||December 31, 2018|
|Actual Study Completion Date :||December 31, 2019|
Active Comparator: probiotic
Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
Dietary Supplement: Winclove 851 and 110
prebiotic and probiotic mixture
Placebo Comparator: placebo
a similar looking and tasting placebo without bacteria
Dietary Supplement: Placebo
white powder without pro/probiotic
- insulin sensitivity [ Time Frame: 12 months ]meal tolerance test
- gut microbiota composition [ Time Frame: 12 months ]next generation sequencing
- gut permeability [ Time Frame: 12 months ]enzyme linked immunosorbent assay
- endotoxin [ Time Frame: 12 months ]limulus amoebocyte assay
- neutrophil function [ Time Frame: 12 months ]flow cytometry
- beta cell function [ Time Frame: 12 months ]meal tolerance test
- Quality of Life [ Time Frame: 12 months ]quality of life questionnaire (short form 36, Subscores for 8 domains)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02469558
|Medical University of Graz, Department of Internal Medicine|
|Graz, Austria, 8036|
|Principal Investigator:||Vanessa Stadlbauer-Köllner, MD||Medical University of Graz|
|Principal Investigator:||Harald Sourij, MD||Medical University of Graz|